Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) shot up 0.6% during trading on Wednesday . The stock traded as high as $1.81 and last traded at $1.80. Approximately 3,057 shares traded hands during trading, a decline of 65% from the average session volume of 8,795 shares. The stock had previously closed at $1.79.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Innate Pharma in a research report on Tuesday, April 7th. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.
Get Our Latest Stock Analysis on IPHA
Innate Pharma Stock Performance
Hedge Funds Weigh In On Innate Pharma
Large investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in Innate Pharma in the fourth quarter worth $36,000. OLD Mission Capital LLC purchased a new stake in shares of Innate Pharma during the fourth quarter valued at $50,000. Finally, Jane Street Group LLC purchased a new stake in shares of Innate Pharma during the fourth quarter valued at $162,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Further Reading
- Five stocks we like better than Innate Pharma
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
